High viscosity macromolecular compositions for treating ocular conditions
Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
1. A method for treating a posterior ocular condition, the method comprising:
administering into the vitreous of an eye of a mammal suffering from an ocular condition a composition consisting of;
a therapeutically effective amount of a macromolecular anti-angiogenic component (MAAC), wherein the MAAC is selected from a VEGF antibody comprising bevacizumab, a VEGF antibody fragment comprising ranibizumab, a VEGF antibody mimic comprising CT-322, C7S100, or C7C100, and combinations thereof;
a viscosity inducing component in an amount effective to increase the viscosity of the composition to a viscosity at about 25° C. of at least 10 cps at a shear rate of about 0.1/second, wherein said viscosity inducing component is injectable into the vitreous of a mammalian eye without permanently diminishing visual acuity,
sodium chloride,
dibasic sodium phosphate heptahydrate, monobasic sodium phosphate monohydrate, and
water;
wherein the posterior ocular condition is selected from macular edema, macular degeneration, diabetic retinopathy, and combinations thereof; and
wherein the administering is by subconjunctival, suprachoroidal, intravitreal or combination thereof.
2. The method of claim 1 wherein said viscosity inducing component comprises a compound having a molecular weight in the range from about 10,000 Daltons to about 2 million Daltons.
3. The method of claim 1 wherein said viscosity inducing component comprises a compound having a molecular weight in the range of about 100,000 Daltons to about 1.5 million Daltons.
4. The method of claim 1 wherein said viscosity inducing component comprises a compound having a molecular weight in the range of about 200,000 Daltons to about 1 million Daltons.
5. The method of claim 1 wherein said viscosity inducing component has a viscosity of at least 100 cps at a shear rate of 0.1/second at 25° C.
6. The method of claim 1 wherein said viscosity inducing component has a viscosity of at least 1000 cps at a shear rate of 0.1/second at 25° C.
7. The method of claim 1 wherein said viscosity inducing component has a viscosity of at least 10,000 cps at a shear rate of 0.1/second at 25° C.
8. The method of claim 1 wherein said viscosity inducing component has a viscosity of at least 70,000 cps at a shear rate of 0.1/second at 25° C.
9. The method of claim 1 wherein said viscosity inducing component has a viscosity of at least 200,000 cps at a shear rate of 0.1/second at 25° C.
10. The method of claim 1 wherein said viscosity inducing component has a viscosity of at least 250,000 cps at a shear rate of 0.1/second at 25° C.
11. The method of claim 1 wherein said viscosity inducing component has a viscosity of at least 300,000 cps at a shear rate of 0.1/second at 25° C.
12. The method of claim 1 wherein said composition is administered to the vitreous of said eye by placement into the vitreous of the eye through a 27-gauge needle.
13. The method of claim 1 wherein said composition is administered to the vitreous of said eye by placement into the vitreous of the eye through a 30-gauge needle.
14. A method for treating a posterior ocular condition, the method comprising:
administering into the vitreous of an eye of a mammal suffering from an ocular condition a composition consisting of;
a therapeutically effective amount of a MAAC selected from one or more of: a VEGF TRAP; icrucumab, ramucirumab, endostatin, angiostatin, tumstatin, and pigment epithelium derived factor,
a viscosity inducing component in an amount effective to increase the viscosity of the composition to a viscosity at about 25° C. of at least 10 cps at a shear rate of about 0.1/second, wherein said viscosity inducing component is injectable into the vitreous of a mammalian eye without permanently diminishing visual acuity,
sodium chloride,
dibasic sodium phosphate heptahydrate, monobasic sodium phosphate monohydrate, and
water;
wherein the posterior ocular condition is selected from macular edema, macular degeneration, diabetic retinopathy, and combinations thereof; and
wherein the administering is by subconjunctival, suprachoroidal, intravitreal or combination thereof.